• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.

作者信息

Adesanya T M Ayodele, Campbell Courtney M, Cheng Lijun, Ogbogu Princess U, Kahwash Rami

机构信息

Department of Family and Community Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

出版信息

J Clin Immunol. 2021 May;41(4):729-732. doi: 10.1007/s10875-021-00972-1. Epub 2021 Jan 21.

DOI:10.1007/s10875-021-00972-1
PMID:33474624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7817248/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9b/7817248/a2cf3eaa2a00/10875_2021_972_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9b/7817248/a2cf3eaa2a00/10875_2021_972_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1e9b/7817248/a2cf3eaa2a00/10875_2021_972_Fig1_HTML.jpg

相似文献

1
C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.C1酯酶抑制：针对新冠病毒中的多个系统
J Clin Immunol. 2021 May;41(4):729-732. doi: 10.1007/s10875-021-00972-1. Epub 2021 Jan 21.
2
Is the COVID-19 thrombotic catastrophe complement-connected?新冠病毒引发的血栓性灾难与补体系统有关吗？
J Thromb Haemost. 2020 Nov;18(11):2812-2822. doi: 10.1111/jth.15050. Epub 2020 Sep 18.
3
Thromboinflammation Supports Complement Activation in Cancer Patients With COVID-19.血栓炎症支持 COVID-19 癌症患者的补体激活。
Front Immunol. 2021 Aug 18;12:716361. doi: 10.3389/fimmu.2021.716361. eCollection 2021.
4
The case of complement inhibitors.补体抑制剂案例。
Adv Biol Regul. 2021 Aug;81:100822. doi: 10.1016/j.jbior.2021.100822. Epub 2021 Aug 19.
5
Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation.人类实体器官移植中 C1 酯酶抑制剂的最新进展。
Transplantation. 2019 Sep;103(9):1763-1775. doi: 10.1097/TP.0000000000002717.
6
Complement C5 inhibition in patients with COVID-19 - a promising target?新冠病毒肺炎患者中补体C5抑制——一个有前景的靶点？
Haematologica. 2020 Dec 1;105(12):2847-2850. doi: 10.3324/haematol.2020.260117.
7
Recruitment of Human C1 Esterase Inhibitor Controls Complement Activation on Blood Stage Merozoites.人C1酯酶抑制剂的募集可控制血液阶段裂殖子上的补体激活。
J Immunol. 2017 Jun 15;198(12):4728-4737. doi: 10.4049/jimmunol.1700067. Epub 2017 May 8.
8
Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.冠状病毒病（COVID-19）中的补体抑制：一种被忽视的治疗选择。
Front Immunol. 2020 Jul 7;11:1661. doi: 10.3389/fimmu.2020.01661. eCollection 2020.
9
Mapping the binding site of C1-inhibitor for polyanion cofactors.绘制 C1 抑制剂与多阴离子辅因子结合部位的图谱。
Mol Immunol. 2020 Oct;126:8-13. doi: 10.1016/j.molimm.2020.06.018. Epub 2020 Jul 24.
10
COVID19 infection in a patient with paroxysmal nocturnal hemoglobinuria: A case report.COVID19 感染阵发性睡眠性血红蛋白尿症患者：病例报告。
Medicine (Baltimore). 2021 May 21;100(20):e25456. doi: 10.1097/MD.0000000000025456.

引用本文的文献

1
Patterns of C1-Inhibitor Plasma Levels and Kinin-Kallikrein System Activation in Relation to COVID-19 Severity.与新冠病毒疾病严重程度相关的C1抑制物血浆水平及激肽-激肽释放酶系统激活模式
Life (Basel). 2024 Nov 21;14(12):1525. doi: 10.3390/life14121525.
2
"Super" SERPINs-A stabilizing force against fibrinolysis in thromboinflammatory conditions.“超级”丝氨酸蛋白酶抑制剂——血栓炎症状态下对抗纤维蛋白溶解的稳定力量。
Front Cardiovasc Med. 2023 Apr 19;10:1146833. doi: 10.3389/fcvm.2023.1146833. eCollection 2023.
3
SerpinG1: A Novel Biomarker Associated With Poor Coronary Collateral in Patients With Stable Coronary Disease and Chronic Total Occlusion.

本文引用的文献

1
Angioedema in African American Patients Hospitalized for COVID-19.因新冠肺炎住院的非裔美国患者的血管性水肿
Am J Respir Crit Care Med. 2020 Dec 1;202(11):1581-1584. doi: 10.1164/rccm.202006-2223LE.
2
The opening salvo of anti-complement therapy against COVID-19.针对新冠病毒的抗补体疗法的首次出击。
Lancet Rheumatol. 2020 Dec;2(12):e729-e730. doi: 10.1016/S2665-9913(20)30353-2. Epub 2020 Sep 28.
3
Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System.
SerpinG1：稳定型冠心病和慢性完全闭塞患者中与较差侧支循环相关的新型生物标志物。
J Am Heart Assoc. 2022 Dec 20;11(24):e027614. doi: 10.1161/JAHA.122.027614. Epub 2022 Dec 14.
4
Non-alcoholic fatty liver disease and liver secretome.非酒精性脂肪性肝病与肝脏分泌组。
Arch Pharm Res. 2022 Dec;45(12):938-963. doi: 10.1007/s12272-022-01419-w. Epub 2022 Nov 28.
5
Targeting thromboinflammation in COVID-19 - A narrative review of the potential of C1 inhibitor to prevent disease progression.靶向 COVID-19 中的血栓炎症 - C1 抑制剂预防疾病进展的潜力述评。
Mol Immunol. 2022 Oct;150:99-113. doi: 10.1016/j.molimm.2022.08.008. Epub 2022 Aug 22.
6
Pathophysiology of COVID-19: Critical Role of Hemostasis.新型冠状病毒肺炎的病理生理学：止血的关键作用。
Front Cell Infect Microbiol. 2022 Jun 3;12:896972. doi: 10.3389/fcimb.2022.896972. eCollection 2022.
7
Therapeutics for COVID-19 and post COVID-19 complications: An update.新型冠状病毒肺炎及其后遗症的治疗：最新进展
Curr Res Pharmacol Drug Discov. 2022;3:100086. doi: 10.1016/j.crphar.2022.100086. Epub 2022 Feb 4.
8
COVID-19, Pre-Eclampsia, and Complement System.COVID-19、子痫前期与补体系统
Front Immunol. 2021 Nov 17;12:775168. doi: 10.3389/fimmu.2021.775168. eCollection 2021.
9
The case of complement inhibitors.补体抑制剂案例。
Adv Biol Regul. 2021 Aug;81:100822. doi: 10.1016/j.jbior.2021.100822. Epub 2021 Aug 19.
用康替沙肽（一种补体、接触激活和激肽释放酶-激肽系统调节剂）治疗 COVID-19。
Front Immunol. 2020 Aug 14;11:2072. doi: 10.3389/fimmu.2020.02072. eCollection 2020.
4
Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19.COVID-19 患者使用激肽 B2 受体拮抗剂的相关结局。
JAMA Netw Open. 2020 Aug 3;3(8):e2017708. doi: 10.1001/jamanetworkopen.2020.17708.
5
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection.免疫补体和凝血功能障碍与 SARS-CoV-2 感染的不良结局。
Nat Med. 2020 Oct;26(10):1609-1615. doi: 10.1038/s41591-020-1021-2. Epub 2020 Aug 3.
6
Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.COVID-19 患者血清的蛋白质组学和代谢组学特征。
Cell. 2020 Jul 9;182(1):59-72.e15. doi: 10.1016/j.cell.2020.05.032. Epub 2020 May 28.
7
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients.COVID-19 患者呼吸道中的先天免疫反应增强。
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2. doi: 10.1016/j.chom.2020.04.017. Epub 2020 May 4.
8
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.COVID-19 患者支气管肺泡免疫细胞的单细胞景观。
Nat Med. 2020 Jun;26(6):842-844. doi: 10.1038/s41591-020-0901-9. Epub 2020 May 12.
9
A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications.COVID-19 呼吸并发症中血管紧张素转化酶 2 下调作用的假设。
FASEB J. 2020 Jun;34(6):7265-7269. doi: 10.1096/fj.202000967. Epub 2020 May 2.
10
The trinity of COVID-19: immunity, inflammation and intervention.COVID-19 的三位一体：免疫、炎症和干预。
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.